Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 5/2011

01-10-2011

Appropriate Antibiotic Dosage Levels in the Treatment of Severe Sepsis and Septic Shock

Authors: Fabio Silvio Taccone, Maya Hites, Marjorie Beumier, Sabino Scolletta, Frédérique Jacobs

Published in: Current Infectious Disease Reports | Issue 5/2011

Login to get access

Abstract

Antibiotic treatment of critically ill patients remains a significant challenge. Optimal antibacterial strategy should achieve therapeutic drug concentration in the blood as well as the infected site. Achieving therapeutic drug concentrations is particularly difficult when infections are caused by some pathogens, such as Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative rods, because of their low susceptibility to antimicrobials. In sepsis, pharmacokinetics (PKs) of antibiotics are profoundly altered and may result in inadequate drug concentrations, even when recommended regimens are used, which potentially contribute to increased mortality and spread of resistance. The wide inter-individual PK variability observed in septic patients strongly limits the a priori prediction of the optimal dose that should be administered. Higher than standard dosages are necessary for the drugs, such as β-lactams, aminoglycosides, and glycopeptides, that are commonly used as first-line therapy in these patients to maximize their antibacterial activity. However, the benefit of reaching adequate drug concentrations on clinical outcome needs to be further determined.
Literature
1.
Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10.PubMedCrossRef
2.
Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–54.PubMedCrossRef
3.
Vincent JL, Sakr Y, Sprung C, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34:344–53.PubMedCrossRef
4.
Dellinger P, Levy M, Carlet J, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock. Crit Care Med. 2008;36:296–327.PubMedCrossRef
5.
Lin MY, Weinstein RA, Hota B. Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother. 2008;52:3188–94.PubMedCrossRef
6.
Chaubey VP, Pitout JD, Dalton B, et al. Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. BMC Res Notes. 2010;3:116.PubMedCrossRef
7.
Kumar A, Roberts D. Kenneth, et al.: Duration of hypotension before administration of effective antimicrobial therapy is the critical determinant. Crit Care Med. 2006;34:1589–96.PubMedCrossRef
8.
• Garnacho-Montero J, Ortiz C, Herrera I, et al.: Mortality and morbidity attributable to inadequate empirical therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother 2008, 61:436–441. This study showed that inadequate antimicrobial therapy at admission to the ICU with sepsis is associated with excess mortality and increased length of stay.PubMedCrossRef
9.
Kollef M, Sherman G, Ward S, et al. Inadequate Antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest. 1999;115:463–74.
10.
Harbarth S, Garbino J, Pugin J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003;31:390–4.
11.
Khollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000;31 Suppl 4:S131–8.CrossRef
12.
Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003;37:745–51.PubMedCrossRef
13.
Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338–48.PubMedCrossRef
14.
Reese AM, Frei CR, Burgess DS. Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms. Int J Antimicrob Agents. 2005;26:114–9.PubMedCrossRef
15.
Bhat SV, Peleg AY, Lodise Jr TP, et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother. 2007;51:4390–5.PubMedCrossRef
16.
• Tam VH, Gamez EA, Weston JS, et al.: Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008, 46:862–7. This study showed that in Pseudomonas aeruginosa bacteremia due to isolates with reduced piperacillin-tazobactam susceptibility, empirical therapy with this drug was associated with increased mortality. PubMedCrossRef
17.
Zaske DE, Sawchuk RJ, Gerding DN, et al. Increased dosage requirements of gentamicin in burn patients. J Trauma. 1976;16:824–8.PubMedCrossRef
18.
Hassan E, Ober JD. Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients. Antimicrob Agents Chemother. 1987;31:1855–8.PubMed
19.
Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44:1009–34.PubMedCrossRef
20.
MacNamara PJ, Gibaldi M, Stoeckel K. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. Eur J Clin Pharmacol. 1983;25:407–12.CrossRef
21.
• Udy A, Boots R, Senthuran S, et al.: Augmented creatinine clearance in traumatic brain injury. Anesth Analg. 2010, 111:1505–10. This study showed that augmented creatinine clearence was common in ICU patients and may have an impact of drug elimination. PubMedCrossRef
22.
Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41:1159–66.PubMedCrossRef
23.
Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother. 2003;51:347–52.PubMedCrossRef
24.
• Roberts JA, Lipman J: Pharmacokinetic issues for antibiotics in the critically ill patients. Crit Care Med 2009, 37:840–851. This is an extensive review of pharmacokinetic and pharmacodynamic issues of antibiotics in ICU patients. PubMedCrossRef
25.
Kiem S, Schentag JJ. Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia. Semin Respir Crit Care Med. 2006;27:51–67.PubMedCrossRef
26.
Abbo A, Carmeli Y, Navon-Venezia S, et al. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis. 2007;26:793–800.PubMedCrossRef
27.
Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med. 2009;37:1463–9.PubMedCrossRef
28.
Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother. 1998;42:2375–9.PubMed
29.
Mouton JW, Punt N. Use of the t>MIC to choose between different dosing regimens of beta-lactam antibiotics. J Antimicrob Chemother. 2001;47:500–1.PubMedCrossRef
30.
Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38:931–6.PubMed
31.
Bedenić B, Vranes J, Sviben M, et al. Postantibiotic and post-beta-lactamase inhibitor effect of carbapenems combined with EDTA against Pseudomonas aeruginosa strains producing VIM-metallo beta-lactamases. Chemotherapy. 2008;54:188–93.PubMedCrossRef
32.
Vogelman B, Gudmundsson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy. J Infect Dis. 1988;158:831–47.PubMedCrossRef
33.
Tam VH, McKinnon PS, Akins RL, et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002;50:425–8.PubMedCrossRef
34.
35.
Nicolau DP, Onyeji CO, Zhong M, et al. Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations. Antimicrob Agents Chemother. 2000;44:1291–5.PubMedCrossRef
36.
•• McKinnon PS, Paladino JA, Schentag JJ: Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31:345–351. This study has shown for the first time the relationship between the pharmacodynamic parameter of cephalosporins (T>MIC) and outcomes in human infections. PubMedCrossRef
37.
Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984;149:443–8.PubMedCrossRef
38.
Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984;77:657–62.PubMedCrossRef
39.
Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93–9.PubMedCrossRef
40.
Kashuba AD, Nafziger AN, Drusano GL, Bertino Jr JS. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43:623–9.PubMed
41.
Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of a single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:796–809.PubMedCrossRef
42.
Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:786–95.PubMedCrossRef
43.
Petrosillo N, Drapeau CM, Agrafiotis M, et al. Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobial in intensive care. Minerva Anesthesiol. 2010;76:509–24.
44.
Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43:1549–55.PubMed
45.
46.
Knudsen JD, Fuursted K, Raber S, et al. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae and Staphylococcus aureus infection. Antimicrob Agents Chemother. 2000;44:1247–54.PubMedCrossRef
47.
Larsson AJ, Walker KJ, Raddatz JK, et al. The concentration-indipendent effect of monoexponential and bioexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother. 1996;38:589–97.PubMedCrossRef
48.
Lodwin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 1998;42:2739–44.
49.
Moise PA, Forrest A, Bhavnani SM, et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm. 2000;57 Suppl 2:S4–9.PubMed
50.
Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clin Biochem Rev. 2010;31(1):21–4.PubMed
51.
•• Rybak MJ, Lomaestro BM, Rotschafer JC, et al.: Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325–7. These are guidelines for the use of vancomycin in different Gram-positive infections, including those due to MRSA. PubMedCrossRef
52.
Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398–402.PubMedCrossRef
53.
Panday PN, Sturkenboom M. Continuous infusion of vancomycin less effective and safe than intermittent infusion, based on pharmacodynamic and pharmacokinetic principles. Clin Infect Dis. 2009;49:1964–5.PubMedCrossRef
54.
Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int. 2010;77:760–4.PubMedCrossRef
55.
Ambrose PG, Owens Jr RC, Garvey MJ, et al. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother. 2002;49:445–53.PubMedCrossRef
56.
Ikawa K, Morikawa N, Hayato S, et al. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients. Int J Antimicrob Agents. 2007;30:270–3.PubMedCrossRef
57.
Lipman J, Gomersall CD, Gin T, et al. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother. 1999;43:309–11.PubMedCrossRef
58.
Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother. 1999;43:2559–61.PubMed
59.
Young RJ, Lipman J, Gin T, et al. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother. 1997;40:269–73.PubMedCrossRef
60.
Benko AS, Cappelletty DM, Kruse JA, et al. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother. 1996;40:691–5.PubMed
61.
• Roberts JA, Kirkpatrick CM, Roberts MS, et al.: First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010, 35:156–163. This study showed that administration of piperacillin by continuous infusion, with a loading dose, achieved superior pharmacodynamic targets compared with conventional bolus dosing in septic patients. PubMedCrossRef
62.
Boselli E, Breilh D, Cannesson M, et al. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 2004;30:976–9.PubMedCrossRef
63.
Kitzes-Cohen R, Farin D, Piva G, et al. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents. 2002;19:105–10.PubMedCrossRef
64.
de Stoppelaar F, Stolk L, van Tiel F, et al. Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia. J Antimicrob Chemother. 2000;46:150–1.PubMedCrossRef
65.
Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother. 2005;49:1337–9.PubMedCrossRef
66.
•• Taccone FS, Laterre PF, Durgernier T, et al.: Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Critical Care 2010, 14:R126. This study analyzed a large cohort of septic patients and showed that recommended doses of cefepime, ceftazidime and piperacillin are insufficient to provide adequate drug concentrations to treat less susceptible strains, in the early phase of sepsis. PubMedCrossRef
67.
•• Roberts JA, Ulldemolins M, Roberts MS, et al.: Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010, 36:332–339. This study provided the monitoring of several antibiotics in a large cohort of ICU septic patients, showing that dose adjustement are necessary to optimize drug concentrations in most of them. PubMedCrossRef
68.
Zeitlinger MA, Erovic BM, Sauermann R, et al. Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis. J Antimicrob Chemother. 2005;56:703–8.PubMedCrossRef
69.
Klekner A, Bagyi K, Bognar L, et al. Effectiveness of cephalosporins in the sputum of patients with nosocomial bronchopneumonia. J Clin Microbiol. 2006;44:3418–21.PubMedCrossRef
70.
Wise R, Logan M, Cooper M, et al. Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob Agents Chemother. 1990;34:1515–7.PubMed
71.
Lipman J, Gomersall CD, Gin T, et al. Continuous infusion of ceftazidime in intensive care: a randomized clinical trial. J Antimicrob Chemother. 1999;43:309–11.PubMedCrossRef
72.
Rafati MR, Rouini MR, Mojtahedzadeh M, et al. Clinical efficacy of continous infusion of piperacillin compared to intermittent dosing in septic critically ill patients. Int J Antimicrob Agents. 2006;28:122–7.PubMedCrossRef
73.
Lodise Jr TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44:357–63.PubMedCrossRef
74.
Lorente L, Jimenez A, Palmero S, et al. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther. 2007;29:2433–9.PubMedCrossRef
75.
•• Chapuis TM, Giannoni E, Majcherczyk PA, et al.: Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010, 14:R51. This study showed that elevated plasma levels of cefepime were associated with neurological side effects in critically ill patients. PubMedCrossRef
76.
Falagas ME, Kopterides P. Old antibiotics for infections in critically ill patients. Curr Opin Crit Care. 2007;13:592–7.PubMedCrossRef
77.
Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis. 2004;4:519–27.PubMedCrossRef
78.
Paul M, Silbiger I, Grozinsky S, et al.: Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006, CD003344.
79.
Marik PE, Havlik I, Monteagudo FS, et al. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once-versus twice-daily dosing regimens. J Antimicrob Chemother. 1991;27(Suppl C):81–9.PubMed
80.
Lugo-Goytia G, Castaneda-Hernandez G. Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis. Ann Pharmacother. 2000;34:1389–94.PubMed
81.
Beaucaire G, Leroy O, Beuscart C, et al. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother. 1991;27(Suppl C):91–103.PubMed
82.
•• Taccone FS, Laterre PF, Spapen H, et al.: Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Critical Care 2010, 14:R53. This study showed that an higher than recommended loading dose of amikacin was necessary to achieve optimal peak drug concentrations in septic patients. PubMedCrossRef
83.
•• Rea RS, Capitano B, Bies R, et al.: Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008, 30:674–681. This study suggested that higher aminoglycosides regimens are necessary to optimize drug pharmacodynamics in ICU patients. PubMedCrossRef
84.
Buijk SE, Mouton JW, Gyssens IC, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 2002;28:936–42.PubMedCrossRef
85.
Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med. 2003;114:194–8.PubMedCrossRef
86.
Layeux B, Taccone FS, Fagnoul D, et al. Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:4939–41.PubMedCrossRef
87.
• Vázquez M, Fagiolino P, Boronat A, et al.: Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock. Int J Clin Pharmacol Ther 2008, 46:140–145. This study showed that insufficient vancomycin concentrations were obtained by conventional regimens in septic patients. PubMed
88.
• Patanwala AE, Norris CJ, Nix DE, et al.: Vancomycin dosing for pneumonia in critically ill trauma patients. J Trauma 2009, 67:802–804. This study showed that insufficient vancomycin concentrations were obtained by conventional regimens in trauma patients with pneumonia. PubMedCrossRef
89.
Kitzis MD, Goldstein FW. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect. 2006;12:92–5.PubMedCrossRef
90.
Pea F, Viale P. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? Clin Pharmacokinet. 2008;47:147–52.PubMedCrossRef
91.
Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004;29:351–7.PubMedCrossRef
92.
Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001;45:2460–7.PubMedCrossRef
93.
Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by methicillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med. 2005;33:1983–7.PubMedCrossRef
94.
Ingram PR, Lye DC, Fisher DA, et al. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2009;34:570–4.PubMedCrossRef
95.
•• Pea F, Furlanut M, Negri C, et al.: Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2009, 53:1863–7. This study provided a first normogram to adjust continuous infusion of vancomycin in critically ill patients. PubMedCrossRef
96.
•• Jeurissen A, Sluyts I, Rutsaert R: A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int J Antimicrob Agents 2011, 37:75–7. This study suggested the need for higher than recommended vancomycin dosage by continuous infusion in ICU patients. PubMedCrossRef
97.
•• Roberts JA, Taccone FS, Udy AA, et al.: Vancomycin dosing in critically ill patients - robust methods for improved continuous infusion regimens. Antimicrob Agents Chemother 2011 (Epub ahead of print). This study provided new propositions to optimize continuous infusion of vancomycin in septic patients during the early phase of therapy.
98.
Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49:71–87.PubMedCrossRef
Metadata
Title
Appropriate Antibiotic Dosage Levels in the Treatment of Severe Sepsis and Septic Shock
Authors
Fabio Silvio Taccone
Maya Hites
Marjorie Beumier
Sabino Scolletta
Frédérique Jacobs
Publication date
01-10-2011
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 5/2011
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-011-0203-y

Other articles of this Issue 5/2011

Current Infectious Disease Reports 5/2011 Go to the issue

ReviewPaper

When and How to Cover for Resistant Gram-Negative Bacilli in Severe Sepsis and Septic Shock

ReviewPaper

Early and Adequate Antibiotic Therapy in the Treatment of Severe Sepsis and Septic Shock

ReviewPaper

Soft Tissue Infections Caused by Marine Bacterial Pathogens: Epidemiology, Diagnosis, and Management

ReviewPaper

When and How to Cover for Fungal Infections in Patients with Severe Sepsis and Septic Shock

ReviewPaper

Antibiotic Therapy in Neonatal and Pediatric Septic Shock

ReviewPaper

What’s New in the Management of Bacterial Septic Arthritis?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits